EMAIL THIS PAGE TO A FRIEND

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology

The efficacy of amlexanox OraDisc on the prevention of recurrent minor aphthous ulceration.


PMID 16430743

Abstract

The study was designed to determine the efficacy of OraDisc (active component 2 mg amlexanox) on the prevention of aphthous ulcers treated at the prodromal stage. Thermographic imaging was used to confirm the presence of a prodromal ulcer. Fifty-two patients were randomized to receive OraDisc (N = 26) or vehicle patches (N = 26). Patches were applied four times a day for 72 h over the prodromal area. The percentage of subjects who developed an ulcer at 72 h was compared between groups using the Fisher's exact test. About 50% of subjects in the OraDisc group developed an ulcer by day 4 compared with 69% in the vehicle group. Erythema score, ulcer size, pain scores and thermographically active area and temperature all showed trends towards healing in the OraDisc group. The OraDisc prevents ulcers from developing when compared with the vehicle patch.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SML0517
Amlexanox, ≥98% (HPLC)
C16H14N2O4